ライフサイエンスコーパス: sertraline

1 hich were SSRIs (paroxetine, fluoxetine, and sertraline).

2 fluoxetine and improved remission more than sertraline.

3 weeks of open-label treatment with the SSRI sertraline.

4 nction reduces the affinity of membranes for sertraline.

5 elective serotonin reuptake inhibitor (SSRI) sertraline.

6 acceptability in favour of escitalopram and sertraline.

7 with cognitive behavioral therapy than with sertraline.

8 placebo to 226 days in patients treated with sertraline.

9 because they will benefit considerably from sertraline.

10 lized (11)C-DASB, we examined the effects of sertraline.

11 osing) or intermittent (luteal-phase dosing) sertraline.

12 or a flexible daily dose of 50 or 100 mg of sertraline.

13 d umbilical concentrations of fluoxetine and sertraline.

14 had fewer side effects with escitalopram and sertraline.

15 ioning with CBT-ip for PNES without and with sertraline.

16 een in the patients showing poor response to sertraline.

17 days before treatment diminished over time (sertraline, -0.7 [3.4] days; placebo, -1.0 [3.2] days),

18 Interventions: Placebo or sertraline, 100 mg/d, for 24 weeks or until development

19 line 109, nortriptyline 114, paroxetine 118, sertraline 124, suloctidil 125, and terfenadine 127.

20 placebo) and the end point (15.3 [10.7] for sertraline; 17.8 [11.0] for placebo) favored the sertral

21 7 participants received at least one dose of sertraline; 181 nonresponders (LSAS score >50) at week 1

22 signed to receive 14 weeks of treatment with sertraline (200 mg/day [N=40]), naltrexone (100 mg/day [

23 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200

24 S-C scores between baseline (35.4 [10.7] for sertraline; 32.8 [10.4] for placebo) and the end point (

25 nse at endpoint was significantly higher for sertraline (45%) than for placebo (35%), and the time to

26 d, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day versus matching placebo for

27 4 months of aerobic exercise (3 times/week), sertraline (50-200 mg/day), or placebo.

28 Whether higher doses of omega-3 or sertraline, a different ratio of EPA to DHA, longer trea

29 nvestigated the transgenerational effects of sertraline, a selective serotonin reuptake inhibitor, an

30 one (abstinence rate: 21.3%; delay=29 days), sertraline (abstinence rate: 27.5%; delay=23 days), and

31 when comparing the combined treatment group (sertraline/active tDCS) vs sertraline only (mean differe

32 Acute sertraline administration can modulate P-gp activity in

33 day, and 6 of the 11 had a third scan after sertraline administration.

34 The Sertraline Against Depression and Heart Disease in Chron

35 The SADHART-CHF (Sertraline Against Depression and Heart Disease in Chron

36 e [LSAS] score >50) after a 10-week trial of sertraline alone: the addition of up to 3.0 mg/day of cl

37 likelihood of substantially benefiting from sertraline among patients with SAD.

38 ed drug screen, we identified the ability of sertraline (an antidepressant) to block the formation of

39 A total of 371 patients assigned to sertraline and 376 assigned to placebo took at least one

40 to treatment (77 of 115 patients [67.0%] for sertraline and 65 of 124 [52.4%] for placebo; chi21 = 5.

41 The combination of sertraline and CBT significantly reduced clinician-repor

42 Sertraline and citalopram have demonstrated efficacy for

43 e of up to 200 mg per day), a combination of sertraline and cognitive behavioral therapy, or a placeb

44 es for CSM-contraindicated SSRIs citalopram, sertraline and especially paroxetine dropped dramaticall

45 Maternal doses of sertraline and fluoxetine correlated with umbilical cord

46 To examine the influence of both sertraline and improvement in mood on HRV.

47 f two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.

48 Sertraline and norsertraline were the most abundant anti

49 patients with CHD and major depression with sertraline and omega-3 fatty acids did not result in sup

50 significant associations between the use of sertraline and omphalocele (odds ratio, 5.7; 95% CI, 1.6

51 The lowest ratios were for sertraline and paroxetine; the highest were for citalopr

52 oups, while change from baseline between the sertraline and placebo groups was significantly differen

53 d, and adverse effects were mild in both the sertraline and placebo groups.

54 pression outcomes at 10 weeks, compared with sertraline and placebo.

55 n period, all patients were given 50 mg/d of sertraline and randomized in double-blind fashion to rec

56 rotonin reuptake inhibitors escitalopram and sertraline and the serotonin-norepinephrine reuptake inh

57 tudy was undertaken to establish the dose of sertraline and to evaluate its efficacy for cholestatic

58 significant additional treatment effect for sertraline and venlafaxine compared with fluoxetine.

59 95% CI, 0.59 to 1.93) or between the use of sertraline and ventricular septal defects (relative risk

60 9 studies of topiramate, and 1 study each of sertraline and zonisamide.

61 n Rating Scale total score was -7.1 +/- 0.5 (sertraline) and -6.8 +/- 0.5 (placebo) (p < 0.001 from b

62 mbining approved medications for depression (sertraline) and alcohol dependence (naltrexone) in treat

63 s) (paroxetine, fluoxetine, fluvoxamine, and sertraline) and clomipramine, four study designs, four d

64 rticipants, 125 with PMDD were randomized to sertraline, and 127 to placebo.

65 bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extend

66 ustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlaf

67 behavioral therapy, which was equivalent to sertraline, and all therapies were superior to placebo.

68 commonly used antidepressants (escitalopram, sertraline, and extended-release venlafaxine), using mul

69 ese drugs, including imipramine, citalopram, sertraline, and fluoxetine (Prozac), bound more avidly t

70 onin reuptake inhibitors (SSRIs) fluoxetine, sertraline, and paroxetine were also absent or severely

71 cipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine.

72 pine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine.

73 We observed the participants of the Sertraline Antidepressant Heart Attack Randomized Trial

74 The Sertraline Antidepressant Heart Attack Randomized Trial

75 ts treated with sertraline vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial

76 The Sertraline Antidepressant Heart Attack Trial (SADHART) t

77 Conclusions and Relevance: Sertraline appears to be efficacious to prevent the onse

78 We selected sertraline as a model SSRI for a 28-d study with adult m

79 ining citalopram, loperamide, methadone, and sertraline as model substances were spotted on alginate

80 Depression recovery with sertraline as well as sustained remission with or withou

81 rticipants were randomly assigned to receive sertraline at 200 mg (n=48), 300 mg (n=36), or 400 mg (n

82 bility, the first 60 participants were given sertraline at escalating doses of 100 mg/day, 200 mg/day

83 andomly assigned (1:1) to receive open-label sertraline at predetermined doses of 200 mg/day, 300 mg/

84 14 sessions of cognitive behavioral therapy, sertraline (at a dose of up to 200 mg per day), a combin

85 was increased 5 minutes after treatment with sertraline, but by 60 minutes after sertraline treatment

86 udy, itch scores improved in patients taking sertraline, but worsened in patients taking placebo (P=0

87 ural product (-)-nicotine and antidepressant sertraline by late-stage amination and azidation reactio

88 Sertraline, citalopram and mitrazapine have been shown t

89 The sertraline cohort revealed similar findings, except ther

90 The lithium/sertraline combination group had a significantly higher

91 therapy, sertraline monotherapy, and lithium/sertraline combination therapy were associated with simi

92 The dropout rate was higher in the lithium/sertraline combination treatment group, without any trea

93 However, treatment with sertraline compared with placebo did not provide greater

94 alysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not si

95 Sertraline conferred preventive efficacy for postpartum-

96 Sertraline conferred significantly greater prophylaxis a

97 Sertraline continued at recovery dose or identical-appea

98 , double-dummy, parallel-group, placebo- and sertraline-controlled trial.

99 0 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, dou

100 nts paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%,

101 The efficacy and safety of tDCS and sertraline did not differ.

102 r demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron activity throu

103 The optimum sertraline dose (75-100 mg/day) was well tolerated.

104 Participants receiving any sertraline dose averaged a CSF clearance rate of -0.37 c

105 Flexible sertraline dose was 50-100 mg/day.

106 At endpoint, the patients receiving sertraline evidenced significantly greater improvements

107 Fish plasma levels of sertraline exceeding human therapeutic doses were accura

108 ted in mammals and fish models to respond to sertraline exposure, was selected as an endpoint associa

109 9 of 111 [26%]) than did participants in the sertraline group (46 of 107, 43%; p=0.010) or mirtazapin

110 Twelve subjects in the sertraline group (71%) were classified as having respond

111 aseline QIDS-C16 score was 14.0 (2.4) in the sertraline group (n = 97) and 14.1 (2.4) in the placebo

112 Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of wei

113 9.9%, 40.6%, and 29.5%, respectively, in the sertraline group and 31.1%, 43.8%, and 25.1%, respective

114 The QIDS-C16 score changed by -4.1 in the sertraline group and by -4.2 in the placebo group (betwe

115 raline; 17.8 [11.0] for placebo) favored the sertraline group by 5.14 (95% CI, 1.97-8.31) points (P =

116 cidal ideation, were no more frequent in the sertraline group than in the placebo group.

117 ality of Life Survey (median score, 0 in the sertraline group vs 0 in the placebo group; between-grou

118 in the placebo group, and 30 patients in the sertraline group.

119 between participants in the mirtazapine and sertraline groups (1.16, -0.25 to 2.57; p=0.11); these f

120 Both sertraline groups improved significantly more than the p

121 that were significantly more improved in the sertraline groups were mood and physical symptoms.

122 1 mumol/L and 10 mumol/L; order of potency: sertraline > fluoxetine > paroxetine > fluvoxamine > cit

123 Participants receiving sertraline had faster cryptococcal CSF clearance and a l

124 Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytr

125 plus 2 extra sessions every other week) and sertraline hydrochloride (50 mg/d).

126 No evidence of harm was seen, and sertraline hydrochloride had an overall beneficial effec

127 Sertraline hydrochloride was reported to have anti-Ebola

128 Sertraline hydrochloride was started at 50 mg/d and incr

129 Medication (flexible-dose sertraline hydrochloride) only, cognitive behavioral the

130 Placebo or sertraline hydrochloride, 50 to 100 mg/d, during the sym

131 02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confi

132 Sertraline hydrochloride, mean dosage of 95 mg/d, or ide

133 h the selective serotonin reuptake inhibitor sertraline hydrochloride.

134 ydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride.

135 udies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank poss

136 Sertraline improvement occurred swiftly in the first mon

137 To determine whether treatment with sertraline improves depressive symptoms in patients with

138 depressed individuals were then treated with sertraline in an open-label manner for 8 weeks, and PBMC

139 Treatment with sertraline in depressed post-ACS patients is associated

140 does not differ from continuous dosing with sertraline in premenstrual syndrome treatment.

141 The influence of sertraline in the course of neuropsychological variables

142 Gradual placebo improvement was similar to sertraline in the third month.

143 ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of a list of compounds ranked

144 The authors assessed the efficacy of sertraline in the treatment of night eating syndrome.

145 A combination of 11 with the SSRI sertraline increased the anorectic effect.

146 Sertraline increased the F0-daphnid fecundity whereas it

147 In MDD, the combination of tDCS and sertraline increases the efficacy of each treatment.

148 ne with the SSRIs paroxetine, fluoxetine, or sertraline inhibited insulin-induced Tyr phosphorylation

149 ted enzyme assays, we also demonstrated that sertraline inhibits phospholipase A(1) and phospholipase

150 f vacuolar ATPase activity reduces uptake of sertraline into cells, whereas dysregulation of clathrin

151 lts of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term

152 Sertraline is superior to placebo for the treatment of m

153 Sertraline is the first selective serotonin reuptake inh

154 Nortriptyline, paroxetine, and sertraline may be preferred choices in breast-feeding wo

155 sertraline than fluoxetine, suggesting that sertraline may produce less fetal medication exposure th

156 ; 95% confidence interval: -9.8 to -5.0) and sertraline (mean -6.1; 95% confidence interval: -8.4 to

157 ls and 107 participants allocated to receive sertraline (mean difference 1.17, 95% CI -0.23 to 2.58;

158 ained response was significantly shorter for sertraline (median, 57 versus 61 days).

159 Sertraline might be the best choice when starting treatm

160 igned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment

161 ing strategy, we demonstrated that high dose sertraline monotherapy provided no benefit for the preve

162 Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combinati

163 cebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks at an initial dose of

164 o receive a flexible dosage (50-200 mg/d) of sertraline (n = 189) or matching placebo tablets (n = 18

165 tpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blin

166 el sertraline treatment continued to receive sertraline (n = 79) or placebo (n = 73) and were followe

167 ome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double

168 itch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=2

169 ) were collected from patients randomized to sertraline (n=28) or placebo (n=36).

170 escription for citalopram (N=618,450) or for sertraline (N=365,898), a comparison medication with no

171 ), or combination treatment with lithium and sertraline (N=48).

172 rapy (N=36) or another antidepressant (N=86; sertraline [N=27], sustained-release bupropion [N=28], o

173 tal of 469 patients were randomized (n = 234 sertraline, n = 235 placebo).

174 tion strategy provides relative benefits for sertraline nonresponders in social anxiety disorder.

175 s were observed for a comparison medication, sertraline, not subject to the FDA warning.

176 and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study.

177 Of 14 subjects who took sertraline, one (7%) suffered a recurrence.

178 treatment group (sertraline/active tDCS) vs sertraline only (mean difference, 8.5 points; 95% CI, 2.

179 Analysis of tDCS only vs sertraline only presented comparable efficacies (mean di

180 Use of tDCS only (but not sertraline only) was superior to placebo/sham tDCS.

181 The sertraline-only arm did not show a reduction in seizures

182 There were no improvements in the sertraline-only or treatment-as-usual arms.

183 elective serotonin reuptake inhibitor (SSRI) sertraline or cognitive behavior therapy (CBT), particip

184 e substantially during treatment with either sertraline or placebo (hazard ratio, 2.39; 95% confidenc

185 5 to 20 mg of olanzapine per day plus masked sertraline or placebo at 150 to 200 mg per day.

186 Statistics Manual fourth edition criteria to sertraline or placebo for 12 weeks.

187 were assigned randomly to a 17-week trial of sertraline or placebo immediately after birth and assess

188 ese patients 16 weeks after randomization to sertraline or placebo.

189 zed open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release.

190 erapy (CBT-ip) only, CBT-ip with medication (sertraline), or treatment as usual.

191 eted 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine (all substra

192 d to 8 weeks of treatment with escitalopram, sertraline, or extended-release venlafaxine.

193 te (10-week) randomized trials of bupropion, sertraline, or venlafaxine as an adjunct to a mood stabi

194 of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-release).

195 ipants were then randomized to escitalopram, sertraline, or venlafaxine-extended release, and were as

196 italopram was associated with intolerance to sertraline (P = .04).

197 ents in heart rate variability compared with sertraline (p = 0.093).

198 behavioral therapy (P<0.001), and 54.9% for sertraline (P<0.001); all therapies were superior to pla

199 aking citalopram, fluoxetine, paroxetine, or sertraline participated.

200 onse rate (69% vs 60%, respectively) and low sertraline-placebo response ratio (1.15).

201 aseline severity independently predicted the sertraline-placebo response ratio.

202 randomized using a 2 x 2 factorial design to sertraline/placebo and active/sham tDCS.

203 he endpoint, and 27% of patients assigned to sertraline plus clonazepam achieved remission compared w

204 cantly greater proportion of patients in the sertraline plus clonazepam group (56%) compared with the

205 Sertraline plus clonazepam was associated with a signifi

206 addition of up to 3.0 mg/day of clonazepam (sertraline plus clonazepam), a switch to up to 225 mg/da

207 re >50) at week 10 were randomly assigned to sertraline plus clonazepam, switch to venlafaxine, or se

208 faxine and either sertraline plus placebo or sertraline plus clonazepam.

209 n venlafaxine and sertraline plus placebo or sertraline plus clonazepam.

210 xone (100 mg/day [N=49]), the combination of sertraline plus naltrexone (N=42), or double placebo (N=

211 sed alcohol-dependent patients receiving the sertraline plus naltrexone combination achieved abstinen

212 The sertraline plus naltrexone combination produced a higher

213 remission compared with patients assigned to sertraline plus placebo (17%) or venlafaxine (19%), but

214 lus clonazepam group (56%) compared with the sertraline plus placebo group responding (36%; p=0.027);

215 se parameters between venlafaxine and either sertraline plus placebo or sertraline plus clonazepam.

216 t reach significance between venlafaxine and sertraline plus placebo or sertraline plus clonazepam.

217 prolonged sertraline treatment with placebo (sertraline plus placebo).

218 e plus clonazepam, switch to venlafaxine, or sertraline plus placebo.

219 020) and disability (p=0.0028) compared with sertraline plus placebo; no significant differences were

220 Saturation of lung 5-HT transporters by sertraline prevents the initial trapping of (11)C-DASB.

221 y and microbiological efficacy of adjunctive sertraline, previously shown to have in-vitro and in-viv

222 ents with diabetes, maintenance therapy with sertraline prolongs the depression-free interval followi

223 Oral sertraline raised the 2-min unmetabolized (11)C-DASB per

224 ion (ratios=0.85 and 1.17, respectively) and sertraline (ratios=1.67 and 1.66, respectively).

225 Both cognitive behavioral therapy and sertraline reduced the severity of anxiety in children w

226 L for citalopram, loperamide, methadone, and sertraline, respectively.

227 Since these 3 predictors of sertraline response are independent, having more than 1

228 Both exercise and sertraline resulted in greater reductions in depressive

229 In vitro, sertraline resulted in rapid and potent inhibition of P-

230 rolonged treatment (16 h) of Min6 cells with sertraline resulted in the induction of inducible nitric

231 nd clathrin-coat formation--as modulators of sertraline's action at membranes.

232 Sertraline seems to be an effective, well-tolerated trea

233 ere randomized to 1 of 3 arms: escitalopram, sertraline (serotonin-specific reuptake inhibitors [SSRI

234 ed with the placebo group, those assigned to sertraline showed greater improvement on the total DRSP

235 Escitalopram and sertraline showed the best profile of acceptability, lea

236 The combined arm (CBT-ip with sertraline) showed 59.3% seizure reduction (P = .008) an

237 Sertraline significantly increased ultra low-frequency p

238 Remarkably, sublethal doses of sertraline stimulate growth of mutants with impaired cla

239 om one trial of paroxetine and two trials of sertraline suggest equivocal or weak positive risk-benef

240 pressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extended-rel

241 ing block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45

242 the absence of its putative protein target, sertraline targets phospholipid membranes that comprise

243 rotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers.

244 al serum ratios were significantly lower for sertraline than fluoxetine, suggesting that sertraline m

245 The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%]

246 an prior to ACS responded more frequently to sertraline than to placebo (63% vs 46%, respectively; od

247 treatment compared with 60% after short-term sertraline therapy, with a median time to relapse of 8 m

248 We gave 100 mg/day sertraline to 17 patients, 200 mg/day to 12 patients, 30

249 xin), was co-administered with fluoxetine or sertraline to determine if either compound increased dru

250 These findings do not support the use of sertraline to treat MDD in patients with non-dialysis-de

251 Ultrastructural studies of sertraline-treated cells revealed a phenotype that resem

252 In the sertraline-treated group 9 patients (38%) were full resp

253 The sertraline-treated group had greater improvements in the

254 Seventeen sertraline-treated patients (9%) and 5 placebo patients

255 verse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at

256 DRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo

257 Sertraline-treated patients experienced statistically si

258 More sertraline-treated subjects reported improved functionin

259 o recurrence was significantly longer in the sertraline-treated women than in the placebo-treated wom

260 Higher ultra low-frequency during sertraline treatment and higher low-frequency power in p

261 Both sertraline treatment and symptomatic recovery from depre

262 By 240 minutes after sertraline treatment brain digoxin accumulation was elev

263 recovered from depression during open-label sertraline treatment continued to receive sertraline (n

264 Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced ap

265 Objective: To assess the efficacy of sertraline treatment in preventing depressive disorders

266 (95% CI, 3.1-71.1; chi2 = 4.6; P = .03) for sertraline treatment vs placebo.

267 er the index ACS, nor an initial 6 months of sertraline treatment was associated with long-term morta

268 p to 225 mg/day of venlafaxine, or prolonged sertraline treatment with placebo (sertraline plus place

269 ent with sertraline, but by 60 minutes after sertraline treatment, brain accumulation of digoxin was

270 Intervention Twelve weeks of sertraline treatment, titrated by clinical response.

271 normative pattern in dMDD participants after sertraline treatment.

272 The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind,

273 Several antipsychotic drugs, such as sertraline, trifluoperazine, and fluphenazine, were foun

274 Sertraline, unlike venlafaxine, may turn out to be a tru

275 d protocol-driven, open-label treatment with sertraline, up to 200. mg/d over 10 weeks.

276 icular outflow tract obstruction and between sertraline use and ventricular septal defects.

277 Nortriptyline, paroxetine, and sertraline usually produce undetectable infant levels.

278 the antidepressants (citalopram, paroxetine, sertraline, venlafaxine, and bupropion, and their metabo

279 s ANOVA revealed a significant advantage for sertraline vs placebo for diminishing E-selectin and bet

280 or vomiting occurred more frequently in the sertraline vs placebo group (22.7% vs 10.4%, respectivel

281 othelial biomarkers in patients treated with sertraline vs placebo in the Sertraline AntiDepressant H

282 Treatment with olanzapine/sertraline was associated with higher remission rates du

283 Sertraline was associated with significantly greater imp

284 Treatment with sertraline was associated with substantially less releas

285 This placebo-controlled study of sertraline was designed to confirm the results of non-pl

286 Sertraline was effective and well tolerated by older adu

287 In this 8-week trial, sertraline was effective in the treatment of night eatin

288 Sertraline was safe in patients with significant HF.

289 nt plant where fluoxetine, atorvastatin, and sertraline were detected in fish bile at the downstream

290 rval: -7.6 to -1.5; p = 0.034); exercise and sertraline were equally effective at reducing depressive

291 Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than dulo

292 n of extraction, basic drugs (citalopram and sertraline) were exhaustively extracted, whereas the rec

293 An exception was sertraline, which exhibited a kd value (0.4-0.5 d(-1)) t

294 them substantially increases the benefit of sertraline while reducing the chance of spontaneous reco

295 hat heart failure (HF) patients treated with sertraline will have lower depression scores and fewer c

296 The final LeuBAT mutant binds the SSRI sertraline with a binding constant of 18 nM and displays

297 owed possible associations of paroxetine and sertraline with other specific defects.

298 y 25% of them, including the antidepressants sertraline (Zoloft) and paroxetine (Paxil).

299 have shown that the clinical antidepressant sertraline (Zoloft) is biologically active in model syst

300 sis was performed for all medications except sertraline, zonisamide, and fluoxetine, which are summar